(Q81328025)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18499889%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

Management of early and advanced colorectal cancer: therapeutic issues (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18499889%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

Rowena N Schwartz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18499889%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18499889%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Health-System Pharmacy

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18499889%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18499889%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

11 Suppl 4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18499889%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

S8-14; quiz S22-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18499889%20AND%20SRC:MED&resulttype=core&format=json

Capecitabine as adjuvant treatment for stage III colon cancer

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

New approaches to the adjuvant therapy of colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Cancer survival: time to get moving? Data accumulate suggesting a link between physical activity and cancer survival

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Tamoxifen-related vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Update on capecitabine in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080101

31 March 2020

Identifiers

DOI

10.2146/AJHP080101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18499889%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference